| Selinexor studied in …STUDIED_INderived153 of 153show fewer |
|---|
| → studied in | NCT05432804Phase 1/Phase 2 · recruiting Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment · 153 trials list this drug (62 active) | — | — | Glioblastoma, IDH-Wildtype,MGMT-Methylated Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05099003Phase 1/Phase 2 · recruiting A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) · 153 trials list this drug (62 active) | — | — | Malignant Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06169215Phase 2 · active not recruiting Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05333458Phase 2 · recruiting Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial · 153 trials list this drug (62 active) | — | — | Soft Tissue Sarcoma,Alveolar Soft Part Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04661137Phase 2 · recruiting A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07832227Phase 2 · not yet recruiting Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial · 153 trials list this drug (62 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02436707Phase 2 · active not recruiting Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma · 153 trials list this drug (62 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07623798Phase 3 · recruiting A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04756401Phase 2 · active not recruiting Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06822972Phase 2 · recruiting HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05900882Phase 2 · completed SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07479979Phase 1/Phase 2 · recruiting Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05611931Phase 3 · active not recruiting Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma · 153 trials list this drug (62 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06158841Phase 3 · active not recruiting Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07779031Phase 1/Phase 2 · active not recruiting A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT · 153 trials list this drug (62 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02835222Phase 2 · active not recruiting Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients · 153 trials list this drug (62 active) | — | — | Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06239272Phase 1/Phase 2 · recruiting NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) · 153 trials list this drug (62 active) | — | — | Malignant Myoepithelioma,Atypical Fibroxanthoma,Fibrosarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02343042Phase 1/Phase 2 · recruiting Selinexor and Backbone Treatments of Multiple Myeloma Patients · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02227251Phase 2 · active not recruiting Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · 153 trials list this drug (62 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04442022Phase 2/Phase 3 · active not recruiting A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06813079Phase 2 · recruiting Using Tumor Models to Determine Treatments · 153 trials list this drug (62 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07200102Phase 1 · recruiting Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07632170NA · not yet recruiting The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07626021Phase 2 · not yet recruiting Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms · 153 trials list this drug (62 active) | — | — | Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05322330Phase 2 · completed Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma · 153 trials list this drug (62 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02091245Phase 1 · active not recruiting Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML · 153 trials list this drug (62 active) | — | — | Acute Lymphoblastic Leukemia,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04640779Phase 1 · completed Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Histiocytic and Dendritic Cell Neoplasm,Hodgkin Lymphoma,Multiple Myeloma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07138209Phase 3 · recruiting A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07569757Phase 3 · not yet recruiting Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07574528Phase 2 · not yet recruiting A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05985161Phase 2 · recruiting A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors · 153 trials list this drug (62 active) | — | — | Solid Neoplasm,Rhabdoid Tumor,Wilms Tumor+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04898894Phase 1 · active not recruiting Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia · 153 trials list this drug (62 active) | — | — | Acute Leukemia of Ambiguous Lineage,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07554482Phase 2 · not yet recruiting Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma · 153 trials list this drug (62 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06552559Phase 1/Phase 2 · recruiting Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03555422Phase 3 · completed Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] · 153 trials list this drug (62 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04562389Phase 3 · active not recruiting Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis · 153 trials list this drug (62 active) | — | — | Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04925193Phase 2 · active not recruiting Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07215832available Karyopharm Expanded Access Program for Selinexor · 153 trials list this drug (62 active) | — | — | Sarcoma,Multiple Myeloma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03589222Phase 2 · active not recruiting SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07437170Phase 2 · active not recruiting Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML · 153 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia,Childhood Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04764942Phase 1/Phase 2 · active not recruiting Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05530421Phase 2 · recruiting Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06517511Phase 2 · recruiting Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) · 153 trials list this drug (62 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04414475Phase 2 · recruiting A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04856189Phase 1/Phase 2 · terminated Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma · 153 trials list this drug (62 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216329Phase 1 · active not recruiting Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma · 153 trials list this drug (62 active) | — | — | Glioblastoma,Gliosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05954780active not recruiting Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02069730NA · completed A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes · 153 trials list this drug (62 active) | — | — | Salivary Gland Neoplasm,Malignant Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05028348Phase 3 · active not recruiting A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02199665Phase 1 · completed Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04607772Phase 1/Phase 2 · withdrawn Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07172412Phase 2 · not yet recruiting Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03147885Phase 1/Phase 2 · active not recruiting Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma · 153 trials list this drug (62 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07011056Phase 3 · recruiting A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05698147Phase 1/Phase 2 · recruiting Selinexor in Combination With MTX+Ritu to Treat R/R CNSL · 153 trials list this drug (62 active) | — | — | Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06556199Phase 1/Phase 2 · recruiting A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05035745Phase 1/Phase 2 · recruiting Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) · 153 trials list this drug (62 active) | — | — | Solid Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06114004Phase 2 · recruiting Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc) · 153 trials list this drug (62 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02303392Phase 1 · completed Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma · 153 trials list this drug (62 active) | — | — | Chronic Lymphocytic Leukemia,Prolymphocytic Leukemia,Small Lymphocytic Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05265975Phase 1/Phase 2 · terminated A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL · 153 trials list this drug (62 active) | — | — | Diffuse Large B-Cell Lymphoma,Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02419495Phase 1 · terminated Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies · 153 trials list this drug (62 active) | — | — | Malignant Solid Neoplasm,Melanoma,Malignant Lung Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06449482Phase 1/Phase 2 · terminated Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy · 153 trials list this drug (62 active) | — | — | Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06966154Phase 1/Phase 2 · recruiting A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04811196Phase 1 · completed A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients · 153 trials list this drug (62 active) | — | — | Malignant Peripheral Nerve Sheath Tumor,Soft Tissue Sarcoma,Endometrioid Stromal Sarcoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06900088Phase 2 · not yet recruiting Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients · 153 trials list this drug (62 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia,Chronic Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04256707Phase 1/Phase 2 · completed Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment · 153 trials list this drug (62 active) | — | — | Colorectal Neoplasm,Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04717700Phase 2 · active not recruiting Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06853678NA · recruiting Second-line Immunotherapy for ES-SCLC · 153 trials list this drug (62 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05597345Phase 2 · recruiting Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06452446active not recruiting Telehealth-based Symptom Management for Veterans Treated With Selinexor · 153 trials list this drug (62 active) | — | — | Interdigitating Dendritic Cell Sarcoma,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04782687Phase 2 · active not recruiting Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06225310Phase 1 · recruiting A Trial of Selinexor, Ruxolitinib and Methylprednisolone · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02323880Phase 1 · completed Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas · 153 trials list this drug (62 active) | — | — | Lymphoma,Malignant Solid Neoplasm,Childhood Central Nervous System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04421378Phase 1/Phase 2 · terminated A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma · 153 trials list this drug (62 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03955783Phase 1 · completed Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies · 153 trials list this drug (62 active) | — | — | Non-Hodgkin Lymphoma,Acute Myeloid Leukemia,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05726110Phase 3 · recruiting Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06613035Phase 3 · not yet recruiting Twice-per-weekSelinexor, 2 Days Melphalan · 153 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04768881Phase 2 · terminated Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma · 153 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03110562Phase 3 · completed Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05820763Phase 2 · withdrawn Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05422027Phase 1/Phase 2 · unknown Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05422066Phase 2 · unknown Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma · 153 trials list this drug (62 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03095612Phase 1/Phase 2 · terminated Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) · 153 trials list this drug (62 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05952687Phase 1 · withdrawn Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors · 153 trials list this drug (62 active) | — | — | Central Nervous System Neoplasm,Rhabdoid Tumor,Atypical Teratoid/Rhabdoid Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05983276Phase 2 · recruiting Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer · 153 trials list this drug (62 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04595994Phase 1 · unknown Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma · 153 trials list this drug (62 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06212596Phase 2 · completed Selinexor, Cyclophosphamide and Prednisone in Myeloma · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05577364Phase 1/Phase 2 · unknown Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients · 153 trials list this drug (62 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04877275Phase 2 · unknown ATG-010(Selinexor) in Combination With Chemotherapy in RRMM · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02178436Phase 1/Phase 2 · completed Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer · 153 trials list this drug (62 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Neoplasm,Pancreatic Acinar Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04854434Phase 2 · terminated A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations · 153 trials list this drug (62 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04519476Phase 1 · unknown Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04843579Phase 2 · terminated Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients · 153 trials list this drug (62 active) | — | — | Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04534725Phase 3 · completed COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; · 153 trials list this drug (62 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05822050Phase 2/Phase 3 · unknown An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05951855Phase 2 · unknown Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients · 153 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02299518Phase 1 · completed Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia · 153 trials list this drug (62 active) | — | — | Secondary Acute Myeloid Leukemia,Adult Acute Myeloid Leukemia,Acute Myeloid Leukemia with del(5q)+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03944057Phase 2 · completed A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05852028unknown A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma · 153 trials list this drug (62 active) | — | — | Lymphoma,T-Cell Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05805072NA · unknown Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02120222Phase 1 · completed Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery · 153 trials list this drug (62 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05786989Phase 4 · unknown Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma · 153 trials list this drug (62 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04138381Phase 1/Phase 2 · unknown Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST) · 153 trials list this drug (62 active) | — | — | Gastrointestinal Stromal Tumor,Adult Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05736965Phase 2 · recruiting A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia · 153 trials list this drug (62 active) | — | — | Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05736978Phase 2 · recruiting Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results · 153 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04941937Phase 2 · unknown Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01607892Phase 1 · completed Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer · 153 trials list this drug (62 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01607905Phase 1 · completed Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer · 153 trials list this drug (62 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01986348Phase 2 · terminated Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas · 153 trials list this drug (62 active) | — | — | Glioblastoma,Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02025985Phase 2 · completed Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies · 153 trials list this drug (62 active) | — | — | Ovarian Carcinoma,Cervical Carcinoma,Endometrial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02088541Phase 2 · completed Selinexor (KPT-330) in Older Patients With Relapsed AML · 153 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02138786Phase 2 · terminated Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02146833Phase 2 · terminated SHIP (Selinexor in Hormone Insensitive Prostate Cancer) · 153 trials list this drug (62 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213133Phase 2 · terminated Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas · 153 trials list this drug (62 active) | — | — | Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02314247Phase 2 · terminated Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma · 153 trials list this drug (62 active) | — | — | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma,Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02336815Phase 2 · completed Selinexor Treatment of Refractory Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02389543Phase 1/Phase 2 · withdrawn Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02628704Phase 2 · withdrawn Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02606461Phase 2/Phase 3 · completed Selinexor in Advanced Liposarcoma · 153 trials list this drug (62 active) | — | — | Dedifferentiated Liposarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02186834Phase 1/Phase 2 · completed Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04984330early Phase 1 · withdrawn Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease · 153 trials list this drug (62 active) | — | — | AL Amyloidosis,Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02780609Phase 1/Phase 2 · completed Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02403310Phase 1 · completed A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML · 153 trials list this drug (62 active) | — | — | Leukemia,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05201118Phase 1 · unknown A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02471911Phase 1 · completed KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma · 153 trials list this drug (62 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02384850Phase 1 · terminated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer · 153 trials list this drug (62 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05177276Phase 1/Phase 2 · withdrawn Selinexor Combination Ph 1 Study · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03042819Phase 1 · completed Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas · 153 trials list this drug (62 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02741388Phase 1 · completed A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP · 153 trials list this drug (62 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02249091Phase 2 · completed A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) · 153 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04998760Phase 2 · unknown A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH ) · 153 trials list this drug (62 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04891744Phase 1/Phase 2 · unknown Selinexor in Combination With Thalidomide and Dexamethasone in RRMM · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02485535Phase 1 · completed Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant · 153 trials list this drug (62 active) | — | — | Myelodysplastic Syndrome,Secondary Acute Myeloid Leukemia,Secondary Myelodysplastic Syndrome+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03212937Phase 1 · completed Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma · 153 trials list this drug (62 active) | — | — | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02269293Phase 1 · completed Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers · 153 trials list this drug (62 active) | — | — | Malignant Ovarian Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03880123Phase 1 · withdrawn Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma · 153 trials list this drug (62 active) | — | — | Sarcoma,Ewing Sarcoma,Liposarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02831686Phase 1 · completed A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02402764Phase 2 · completed Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) · 153 trials list this drug (62 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02078349Phase 1 · completed Phase I Study of KPT330 in Asian Patients · 153 trials list this drug (62 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03071276Phase 2 · terminated Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia · 153 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03661515Phase 1 · completed Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML · 153 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02573363Phase 1 · completed Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia · 153 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02530476Phase 1/Phase 2 · completed Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia · 153 trials list this drug (62 active) | — | — | Leukemia,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02212561Phase 1 · completed Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome · 153 trials list this drug (62 active) | — | — | Acute Lymphoblastic Leukemia,Myelodysplastic Syndrome,Acute Myeloid Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02416908Phase 1/Phase 2 · completed Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia · 153 trials list this drug (62 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02250885Phase 2 · completed KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors · 153 trials list this drug (62 active) | — | — | Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03850704no longer available Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma · 153 trials list this drug (62 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02215161Phase 2 · terminated Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer · 153 trials list this drug (62 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03466827Phase 2 · unknown Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma · 153 trials list this drug (62 active) | — | — | Thymus Epithelial Neoplasm,Thymoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02093403Phase 1 · completed Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia · 153 trials list this drug (62 active) | — | — | Secondary Acute Myeloid Leukemia,Acute Myeloid Leukemia,Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02351505Phase 2 · terminated Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer · 153 trials list this drug (62 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02283359Phase 1 · terminated Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus · 153 trials list this drug (62 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02536495Phase 1/Phase 2 · withdrawn Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer · 153 trials list this drug (62 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |